Advertisement


Courtney D. DiNardo, MD, on AML: Venetoclax and Azacitidine for Treatment-Naive Patients

EHA25 Virtual

Advertisement

Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses data from her study of treatment-naive, predominantly older patients with acute myeloid leukemia who are ineligible for intensive therapy. The research shows venetoclax plus azacitidine improved response rates and overall survival compared with azacitidine alone (Abstract LB2601).



Related Videos

Leukemia
Lymphoma

Elias Jabbour, MD, on Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Venetoclax and Navitoclax in Relapsed or Refractory Disease

Elias Jabbour, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings that showed venetoclax and navitoclax with chemotherapy is well tolerated, w...

Leukemia

Abhishek Maiti, MBBS, on AML: Decitabine and Venetoclax vs Intensive Chemotherapy

Abhishek Maiti, MBBS, of The University of Texas MD Anderson Cancer Center, discusses his analysis showing that 10-day decitabine and venetoclax led to superior outcomes comp...

Lymphoma
Immunotherapy

Michael J. Dickinson, MBBS, DMedSc, on Non-Hodgkin Lymphoma: Early Study Findings With Novel T-Cell–Engaging Bispecific Antibody

Michael J. Dickinson, MBBS, DMedSc, of the Peter MacCallum Cancer Centre, discusses phase I dose-escalation study results on CD20-TCB, which showed activity, including durabl...

Leukemia

Anthony Moorman, PhD, on ALL: Improving Outcomes With a Tyrosine Kinase Inhibitor Plus Chemotherapy

Anthony Moorman, PhD, of Newcastle University, discusses preliminary data showing high-risk patients with acute lymphoblastic leukemia and ABL-class mutations may ha...

Immunotherapy

Efstathios Kastritis, MD, on Amyloidosis: Daratumumab Plus Cyclophosphamide, Bortezomib, and Dexamethasone

Efstathios Kastritis, MD, of the University of Athens, discusses phase III findings of the Andromeda study. Adding daratumumab to cyclophosphamide, bortezomib, and dexamethas...

Advertisement

Advertisement



Advertisement